NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every cell of the body. It is the central molecule for energy metabolism, DNA repair, and sirtuin (longevity protein) activation. Human NAD+ levels decline markedly with age—approximately halving every 20 years—forming the scientific rationale behind NAD+ supplementation.
Unlike precursor molecules (NMN, NR) that require enzymatic conversion, liposomal NAD+ delivers the active coenzyme directly, bypassing conversion bottlenecks for the fastest possible onset.
NAD+ is a large, negatively charged molecule with extremely poor membrane permeability. Conventional oral NAD+ is virtually ineffective—destroyed by stomach acid before it reaches circulation.
Our liposomal platform wraps NAD+ in a phospholipid bilayer vesicle that mimics cell membrane structure. This achieves three critical outcomes:
A phospholipid bilayer vesicle engineered at nanoscale to protect and deliver NAD+ directly into cells.
Non-GMO sunflower lecithin
Double-layer membrane mimicking natural cell structure. Hydrophilic heads face outward and inward; hydrophobic tails form the core barrier.
Acid-resistant protection
The lipid tail core blocks gastric acid, enzymes, and oxidation. NAD+ stays intact through stomach transit — no degradation.
≥98% purity active payload
Water-soluble NAD+ encapsulated in the inner aqueous compartment. Protected from the external environment until membrane fusion releases it intracellularly.
Direct intracellular uptake
Liposome bilayer fuses with cell membrane, releasing NAD+ directly into the cytoplasm. Bypasses transport protein limitations — no conversion needed.
Five-stage GMP manufacturing process ensuring uniform particle size and high encapsulation efficiency.
Phospholipids dissolved in organic solvent, dried to a thin film under vacuum. NAD+ aqueous solution added for hydration.
Probe sonication breaks down multi-lamellar vesicles into uniform small unilamellar vesicles (SUVs), 80-200 nm.
High-pressure homogenization at 20,000 psi ensures narrow particle size distribution (PDI < 0.2) and stability.
Sterile filtration (0.22 µm), encapsulation efficiency testing (≥92%), particle size verification, and microbial screening.
Freeze-drying for powder format or aseptic filling for liquid. Full COA issued with every batch.
Research-backed benefits of liposomal NAD+ across multiple health dimensions.
Supports mitochondrial ATP production for improved daily vitality and physical performance.
Activates sirtuin longevity proteins and delays cellular senescence across tissues.
Serves as PARP substrate for genomic integrity maintenance and damage repair.
Reduces senescent cells and protects dermal microvasculature for healthier skin tone.
The first-ever liposomal NAD+ topical anti-aging study (Curr. Issues Mol. Biol. 2025) demonstrated that liposomal NAD+ (LF-NAD+) enhances transdermal penetration by +30% vs free NAD+.
In both epidermal keratinocytes and dermal microvascular endothelial cells, topical LF-NAD+ significantly reduced senescence markers p16 and p21, lowered senescent cell accumulation, and protected the skin microvasculature—key factors for improving skin tone, firmness, and nutrient delivery.
Patent US 12,150,461 B2 · Lecithin / Pentylene Glycol / Glycerin / Tocopherol
Evidence-based product development guidance for your formulations.
| Route | Typical Dosage | Notes |
|---|---|---|
| Oral (Capsule) | 100–300 mg/day | With or without food |
| Topical | 1–5% in formula | 5% w/w per transdermal study |
No unified regulatory dosage. Above ranges reflect commercial products. Not medical advice.
Request samples, review our technical documentation, or speak with a formulation specialist about integrating liposomal NAD+ into your product line.